REV: Responsibly and reliably powering industry
With a focus on the creation of innovative technology and forward-thinking practical solutions, REV offers flexible, durable, reliable
Kramer Mazda: The largest Mazda dealership in Western Canada
The largest Mazda dealership in Calgary and Western Canada, for over 40 years Kramer Mazda has been developing
German-Canadian Care Home: An innovative new vision for elder care
Providing compassionate care to seniors in Vancouver for over 50 years, the German-Canadian Care Home is part of
Hinton Scaffold Solutions: Utilizing innovate technologies to create safer worksites
With many years of experience in the heavy industrial scaffold industry, Ontario-based Hinton Scaffold Solutions provides highly innovative
Alberta Veterinary Laboratories / Solvet: Supporting Canada’s food
Founded in 2009, Western Canadian family-owned pharmaceutical manufacturer Alberta Veterinary Laboratories manufactures and provides efficacious and cost-effective animal
Sodexo Canada: The global leader who believes the difference a day makes
Founded in Marseille in 1966, and now operating in 53 countries, Sodexo provides facilities services that drive positive
Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver
Locally owned-and operated and serving Metro Vancouver and the Fraser Valley, Barclay Restorations DKI is a full-service restoration
CDW Canada: Helping small businesses use IT security to prepare, defend, and respond
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare,
Taiwan: Key to win-win approach for Canadian Industry
Taiwan’s innovation leadership and significant economic potential in Asia is an opportunity for Canada to stay competitive on
Taking charitable giving to the next level
Empowering employees to support the causes that matter most to them is the best way to maximize charitable
Lots of money seeking company acquisitions – The case of private equity
At this time, there is more money in the system than anyone can imagine. It is estimated that
There’s optimism amid instability in the Canadian construction landscape
The last year has been among the most expensive on record for many Canadians. Families and those on
Washed up elites need to stop lecturing the people
The ramblings of ex-Prime Ministers, Presidents and CEOs is a feature of all political life, history and cultures.
The political timing of Finland’s admission into NATO
It has been a few weeks since the world watched the proverbial ink of approval dry on Finland’s
How to manage the stress of making the right business decisions
It can be stressful when you have to make important decisions regarding your business. We all want to
Reclaiming Canada’s key service export: Tourism
Tourism is an increasingly dynamic sector of the global economy; pre-2019 tourism was a $1.4 trillion industry generating
ACERUS ANNOUNCES LICENSING OF NATESTO® IN MAJOR EUROPEAN COUNTRIES
Acerus Pharmaceuticals Corporation (TSX:ASP) has announced the signing of an agreement granting medac Gesellschaft für klinische Spezialpräparate mbH (“medac”) the exclusive right to market NATESTO® in 15 European countries (Germany, United Kingdom, France, Italy, Czech Republic, Slovakia, Spain, Sweden, Finland, Denmark, Norway, Poland, Austria, Netherland and Belgium). medac is a German pharmaceutical company with business in 80 countries and more than 1,200 employees worldwide.
“We are delighted to be partnering with medac for the commercialization of NATESTO® in Europe,” said Tom Rossi, President and Chief Executive Officer of Acerus. “Their extensive reach and commercial expertise within the speciality pharmaceutical sector will be a key advantage as we aim to maximize the full potential of NATESTO®. This agreement represents a significant milestone for Acerus as we continue to execute on our strategy of expanding the brand’s reach on a global scale.”
“We are very pleased to announce this partnership with Acerus as it enables us to provide patients in Europe with an innovative product and address a medical need,” said Dr. Ulrich Kosciessa, Managing Director of medac. “NATESTO® is an important advance for patients suffering from hypogonadism. Its novel nasal administration and unique safety and efficacy profile represent a clear opportunity to improve patient quality of life and represents a perfect fit to our current portfolio. We look forward to working closely with Acerus as we prepare to file NATESTO® for European marketing approval.”
Under the terms of the agreement, Acerus will receive a non-refundable upfront fee and regulatory milestone payments upon medac receiving marketing approval in certain countries as well as milestone payments based on achieving sales targets. In total, Acerus is eligible to receive up to €11,500,000 in upfront and milestone payments. Acerus will oversee the manufacturing of NATESTO® and, in addition, will receive a supply price for the product. If approved, NATESTO® will be the first and only testosterone nasal gel for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism) in Europe.
- Read the current edition
- Recent posts
